文献速递腹部技术与安全CT

双能CT列线图用于无创判断胃癌HER2表达状态

Dual-Energy CT-Based Nomogram for Decoding HER2 Status in Patients With Gastric Cancer.
PubMed 文献 · AJR Am J Roentgenol · 2021-04-14

该回顾性研究纳入206例经组织学确诊的胃癌患者,术前接受双能CT检查,随机分为训练组(144例)和测试组(62例)。研究基于肿瘤部位、静脉期碘浓度及静脉期标准化碘浓度构建列线图,训练组和测试组AUC分别为0.807和0.815,显示良好的鉴别能力和校准度,有望作为无创替代方法检测HER2状态。

要点

  • 静脉期碘浓度及标准化碘浓度是预测胃癌HER2状态的独立因素。
  • 基于双能CT参数构建的列线图在训练组和测试组AUC分别为0.807和0.815。
  • 列线图校准良好,在较宽阈值概率范围内提供净获益,可辅助无创评估HER2状态。

关键影像表现/征象

  • 肿瘤部位是预测HER2状态的显著因素。
  • 静脉期肿瘤碘浓度是预测HER2状态的显著因素。
  • 静脉期肿瘤标准化碘浓度是预测HER2状态的显著因素。

诊断标准与关键数值

  • 列线图在训练组的AUC为0.807(95% CI, 0.718-0.897)。
  • 列线图在测试组的AUC为0.815(95% CI, 0.661-0.968)。
  • Hosmer-Lemeshow检验显示列线图拟合良好(均p > .05)。
  • 列线图在两组较宽阈值概率范围内比简单默认策略提供更多净获益。

临床应用与阅片要点

  • 可结合肿瘤部位、静脉期碘浓度和标准化碘浓度无创评估胃癌HER2状态。
  • 列线图可作为侵入性检测的潜在替代工具,辅助临床决策。

局限性

  • 回顾性研究设计。
  • 单中心样本,样本量有限。
  • 未报告外部验证结果。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

英文原文(摘要)· 点击展开

OBJECTIVE. The purpose of this study was to develop and evaluate a dual-energy CT (DECT)-based nomogram for noninvasive identification of the status of human epidermal growth factor receptor 2 (HER2; also known as ERBB2) expression in gastric cancer (GC). MATERIALS AND METHODS. A total of 206 patients with histologically proven GC who underwent pretreatment DECT were retrospectively recruited and randomly allocated to a training cohort (n = 144) or a test cohort (n = 62). Information on clinical characteristics, qualitative imaging features, and quantitative DECT parameters was collected. Univariate analysis and multivariate logistic regression were implemented to screen independent predictors of HER2 status. An individualized nomogram was built, and its discrimination, calibration, and clinical usefulness were assessed. RESULTS. Tumor location, the iodine concentration of the tumor in the venous phase, and the normalized iodine concentration of the tumor in the venous phase were significant factors predictive of HER2 status (all p < .05). After these three indicators were integrated, the proposed nomogram showed a favorable diagnostic performance, with AUCs of 0.807 (95% CI, 0.718-0.897) in the training cohort and 0.815 (95% CI, 0.661-0.968) in the test cohort. The nomogram showed a preferable fitting (all p > .05 by the Hosmer-Lemeshow test) and would offer more net benefits than simple default strategies within a wide range of threshold probabilities in both cohorts. CONCLUSION. The DECT-based nomogram has great application potential in terms of detecting HER2 status in GC, and can serve as a novel substitute for invasive testing.

来源:AJR Am J Roentgenol,查看原文。版权归原作者所有。

引用

  1. Zhao H, Li W, Huang W, et al. Dual-Energy CT-Based Nomogram for Decoding HER2 Status in Patients With Gastric Cancer. AJR Am J Roentgenol. 2021. PMID: 33852330. doi:10.2214/AJR.20.23528

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。